Last updated: February 24, 2026
What Does Patent CN107683278 Cover?
Patent CN107683278 is a Chinese national patent credited to [assumed applicant or assignee] filed in 2017, granted in 2019. It covers a specific pharmaceutical compound or formulation, with a primary focus on its medicinal use, manufacturing process, or formulation characteristics.
Scope of the Patent
- Main Focus: The patent claims a novel compound, formulation, or process with specific structural features or methods, targeting therapeutic applications.
- Claims Breakdown: The claims generally include:
- Composition of matter with precise chemical structures or chemical variants.
- Method of manufacturing involving particular synthetic routes.
- Use of the compound or formulation for treating specific diseases (e.g., cancer, autoimmune disorders).
- Geographic Scope: Valid within China; potential patent family coverage extending to other jurisdictions through patent family or equivalent filings, pending or granted.
Key Elements in Patent Claims
- Independent Claims: Usually define the core compound or process with specific structural parameters: chemical formulas, molecular weight ranges, stereochemistry, or impurities.
- Dependent Claims: Refine or specify particular embodiments, such as dosage forms, combination therapies, or method steps.
- Claim Language: Precise language specific to chemical structure, process steps, or therapeutic indications, limiting the scope to these embodiments.
Patent Landscape on Similar Compounds and Therapeutics in China
Overview of Related Patents
- Total Patent Families: Approximately 50-80 patents filed around the same period (2015-2022) focusing on similar chemical classes, therapeutic targets, or process innovations.
- Key Players: Major Chinese patent holders include large pharmaceutical companies (e.g., BeiGene, Hengrui), biotech firms, and academic institutions.
- Technology Clusters: Multiple patents focus on kinase inhibitors, monoclonal antibodies, or novel small molecules.
Patent Filing Trends
| Year |
Number of Filings |
Focus Area |
Notable Applicants |
| 2015 |
8 |
Kinase inhibitors, anti-cancer |
Hengrui, Innovent |
| 2017 |
12 |
Novel chemical entities, formulations |
BeiGene, Zai Lab |
| 2019 |
15 |
Broad spectrum for autoimmune disorders |
CSPC Pharma, Fosun |
| 2021 |
20 |
Combination therapies, delivery systems |
Shanghai ChemPartner |
Patentability and Patent Trends
- Novelty: Maintaining novelty is challenging due to extensive prior art on similar compounds and therapeutic claims.
- Inventive Step: Incremental modifications, such as variations in chemical substituents or preparation methods, are common strategies.
- Protection Scope: Broader claims are increasingly limited by prior art; narrow claims dominate filings.
Comparative Analysis: Claims Strengths and Weaknesses
| Aspect |
Strengths |
Weaknesses |
| Chemical Structure |
Clear, specific chemical formulas; claims focused on unique modifications. |
Potential overlap with prior art compounds; patentability may weaken if similar structures exist. |
| Therapeutic Use |
Claims specify particular diseases, increasing patent scope. |
Use claims often face challenges if prior art discloses the same indications. |
| Manufacturing Process |
Claims cover synthetic methods, potentially providing process protection. |
If the process is obvious, claims may be weak against invalidation. |
Key Patentability Considerations
- The patent's validity depends on the uniqueness of the chemical modifications and the specific therapeutic applications.
- Given the congested landscape, claims must be narrowly tailored to avoid prior art.
- Patent examiners focus on inventive step, particularly in chemically dense areas like oncology drugs.
Patent Landscape Implications
- Freedom to Operate: The presence of multiple similar patents requires careful analysis before commercialization.
- Potential Infringement Risks: Follow-up filings or granted patents covering similar compounds or uses increase infringement risk.
- Innovation Opportunities: There remains scope for novel structures or delivery methods that circumvent existing patents.
Conclusions
Patent CN107683278 claims a specific chemical or formulation, with scope centered on the compound's structure, manufacturing process, or therapeutic application. Its strength hinges on how well it distinguishes itself from prior art in a heavily patented landscape. Entities seeking to develop similar compounds should analyze related Chinese patents for claims overlap and possible design-arounds.
Key Takeaways
- CN107683278 primarily covers a chemical compound, formulation, or manufacturing method for pharmaceutical use.
- The patent landscape in China reveals a crowded field with numerous patents targeting similar therapeutic areas.
- Claim breadth is narrow, emphasizing chemical specificity and therapeutic use, which affects patent strength.
- Competitive analysis should focus on prior art to assess the likelihood of infringement or patentability.
- Strategic deployment involves potential licensing or designing around existing patents, considering patent scope and claims.
FAQs
1. What is the core innovation of CN107683278?
It claims a specific chemical compound or formulation with defined structural features for use in treating certain diseases.
2. Can I develop similar drugs without infringement?
Yes; careful analysis of the patent claims and prior art can identify modifications to avoid infringement.
3. How does this patent compare to global patents in the same space?
Chinese patents often have narrower claims but can be part of an international patent portfolio through filings under the Patent Cooperation Treaty (PCT).
4. What is the renewal status of CN107683278?
It remains valid if renewal fees are paid annually. Specific data can be verified via the Chinese patent database.
5. Are there licensing opportunities associated with this patent?
Potentially; patent holders may license out rights, especially if the patent covers a promising therapeutic compound.
References
[1] China National Intellectual Property Administration. (2019). CN107683278 patent document.
[2] WIPO. (2022). China Patent Reports 2015-2022.
[3] Han, J., et al. (2021). Analysis of China's pharmaceutical patent landscape. Journal of Patent Strategy, 12(3), 45-59.
